SCHEMBL7428433

SCHEMBL7428433

COc1ccc(C[C@H](NC(=O)CC(C)(C)N)C(=O)N([C@@H](Cc2c[nH]cn2)C(N)=O)[C@@H](CC2CCCCC2)[C@@H](O)[C@@H](O)CC(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
REN P00797 18/20 0.51
MMP1 P03956 1/20 0.39
PSMB5 P28074 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enalkiren SCHEMBL123107 0.85 REN (0.62) REN
SCHEMBL7335979 0.83 REN (0.53) REN
SCHEMBL7334721 0.79 REN (0.52) REN
SCHEMBL9523860 0.79 REN (0.46) REN
SCHEMBL13754442 0.77 REN (0.65) REN
SCHEMBL7316219 0.76 REN (0.41) REN
SCHEMBL7334725 0.76 REN (0.42) REN
Enalkiren SCHEMBL123108 0.76 REN (0.69) REN
Hydrochloric Acid SCHEMBL7318517 0.76 REN (0.41) REN
SCHEMBL7326151 0.75 REN (0.60) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10668049-B2 Methods of treating cognitive decline with transforming growth factor beta inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-06-02 US disclosed
US-20160367530-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-12-22 US disclosed
US-9468649-B2 Methods of treating epilepsy with transforming growth factor beta inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-10-18 US disclosed
EP-0634175-B1 Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist HOFFMANN LA ROCHE (CH) 2001-01-10 EP disclosed
EP-0425892-A2 Process for enhancing the bioavailability of drugs with peptide bonds BASF Aktiengesellschaft (DE) 1991-05-08 EP disclosed